Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients (Q34401878)

1 August 2017

title

Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients (English)

1 reference

Carlo Gambacorti-Passerini

1 August 2017

1 reference

object named as

Carlo Gambacorti Passerini

1 reference

1 August 2017

Luca Guerra

0 references

Lara Mussolin

0 references

Francesca Farina

1 reference

1 August 2017

Alessandra Stasia

1 reference

1 August 2017

Sara Redaelli

1 reference

1 August 2017

Monica Ceccon

1 reference

1 August 2017

Luca Mologni

1 reference

1 August 2017

Cristina Messa

1 reference

1 August 2017

Giovanni Giudici

1 reference

1 August 2017

Elena Sala

1 reference

1 August 2017

Dries Deeren

1 reference

1 August 2017

Michael H King

1 reference

1 August 2017

Michael Steurer

1 reference

1 August 2017

Rainer Ordemann

1 reference

1 August 2017

Amos M Cohen

1 reference

1 August 2017

Matthias Grube

1 reference

1 August 2017

Lea Bernard

1 reference

1 August 2017

Gianpaolo Chiriano

1 reference

1 August 2017

Laura Antolini

1 reference

1 August 2017

Rocco Piazza

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 February 2014

1 reference

Journal of the National Cancer Institute

1 August 2017

published in

1 reference

1 August 2017

volume

106

1 reference

1 August 2017

1 reference

1 August 2017

page(s)

djt378

1 reference

The anaplastic lymphoma kinase in the pathogenesis of cancer

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT378

CD30-positive large cell lymphomas ('Ki-1 lymphoma') are associated with a chromosomal translocation involving 5q35.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT378

Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT378

Anaplastic large cell lymphoma, ALK-positive

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT378

ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT378

Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT378

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT378

Crizotinib in Anaplastic Large-Cell Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT378

Detection of a subset of CD30+ anaplastic large cell lymphoma by interphase fluorescence in situ hybridization

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT378

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT378

Use of minimal disseminated disease and immunity to NPM-ALK antigen to stratify ALK-positive ALCL patients with different prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT378

Recurrent SETBP1 mutations in atypical chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT378

Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT378

Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT378

Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT378

Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT378

21 January 2018

Identifiers

DOI

10.1093/JNCI/DJT378

1 reference

1 August 2017

1 reference